Immutep (IMMP) has released an update.
Immutep has announced encouraging results from its INSIGHT-003 trial, showing that their drug eftilagimod alpha (efti) combined with KEYTRUDA and chemotherapy significantly improves survival rates in patients with non-small cell lung cancer. The trial data revealed a median overall survival of 32.9 months and a favorable safety profile, exceeding historical benchmarks. These promising results bolster Immutep’s preparations for the upcoming TACTI-004 Phase III trial, potentially setting a new standard of care in lung cancer treatment.
For further insights into IMMP stock, check out TipRanks’ Stock Analysis page.
